Every Form 4 that Invivyd, Inc. (IVVD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow IVVD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IVVD filings page.
Invivyd, Inc. (IVVD) director Ian Sheffield received a grant of stock options for 100,000 shares of common stock on August 31, 2026. The options have an exercise price of $0.9549 per share, expire on August 30, 2036, and are held directly. The grant vests over three years, with one-third vesting on the first anniversary and the remainder vesting in substantially equal monthly installments thereafter, subject to his continuous service. No Rule 10b5-1 trading plan is reported.
Invivyd, Inc. (IVVD) reported that Chief Executive Officer Marc Elia received a grant of stock options to purchase 10,700,000 shares of common stock. The options have an exercise price of $0.9645 per share and expire on August 29, 2036. The grant vests over four years, starting August 30, 2026, with 25% vesting on the first anniversary and the remaining 75% vesting in substantially equal monthly installments over the following three years, subject to continued service.
Invivyd, Inc. (IVVD) reported that Chief Commercial Officer Timothy Edward Lee converted 102,000 restricted stock units into common stock on August 15, 2026, then sold a total of 40,780 common shares in two transactions on August 17–18, 2026. The sales were described as non-discretionary sell-to-cover trades to satisfy tax withholding obligations upon RSU vesting, executed under a Rule 10b5-1 trading plan adopted on February 20, 2025. Reported sale prices are weighted averages across multiple trades within disclosed price ranges.
Invivyd, Inc. (IVVD) reported insider equity transactions by Chief Human Resources Officer Julie Green. On August 15, 2026, 102,000 restricted stock units converted into an equal number of common shares, representing vesting of an RSU award granted February 15, 2025. To satisfy related tax withholding obligations, she then sold 22,355 shares on August 17, 2026 at a weighted-average price of $0.722 per share and 18,425 shares on August 18, 2026 at a weighted-average price of $0.8429, in non-discretionary sell-to-cover transactions executed under a Rule 10b5-1 trading plan adopted February 20, 2025.
Invivyd, Inc. (IVVD) reported that its Chief Financial Officer, William E. Duke, converted 102,000 restricted stock units into an equal number of common shares on August 15, 2026, as part of a scheduled vesting. The underlying RSU award vests in thirds every six months over an eighteen‑month period from February 15, 2025. To cover tax withholding from this vesting, he then sold a total of 40,780 shares of common stock in open-market, non‑discretionary sell‑to‑cover transactions pursuant to a pre‑arranged Rule 10b5‑1 plan adopted on February 20, 2025, at weighted average prices of $0.722 (range $0.682–$0.830) on August 17 and $0.8429 (range $0.760–$0.872) on August 18.
Invivyd, Inc. (IVVD) reported insider equity activity by Chief Legal Officer and Secretary Jill Andersen involving the vesting of 170,000 Restricted Stock Units, each converting into one share of common stock. On August 17, 2026, 37,256 shares of common stock were sold at a weighted average price of $0.722 per share in transactions priced between $0.682 and $0.830. On August 18, 2026, a further 30,706 shares were sold at a weighted average price of $0.8429 per share in transactions priced between $0.760 and $0.872. The sales were described as non-discretionary “sell-to-cover” transactions to satisfy tax withholding obligations upon RSU vesting, conducted under a Rule 10b5-1 plan adopted on February 20, 2025. Following these transactions, an additional 500 shares of common stock are reported as held indirectly by Andersen’s spouse.
Invivyd, Inc. (IVVD) reported insider equity activity by Chief Scientific Officer Robert D. Allen III relating to restricted stock units (RSUs). On August 15, 2026, 102,000 RSUs, each representing one share of common stock, were converted into 102,000 shares of Invivyd common stock as part of an RSU vesting schedule over eighteen months from a February 15, 2025 grant date. In connection with this vesting, Allen executed non-discretionary "sell-to-cover" transactions under a Rule 10b5-1 plan adopted on February 20, 2025, selling 20,679 shares on August 17, 2026 at a weighted average price of $0.722 and 17,043 shares on August 18, 2026 at a weighted average price of $0.8429 to satisfy tax withholding obligations.
Invivyd, Inc. granted Chief Medical Officer and Chief Epidemiologist Michael Mina a stock option for 1,125,000 shares of common stock, with an exercise price of $0.535 per share and expiration on July 30, 2036. The option vests over four years: 25% on July 31, 2027, and the remaining 75% in substantially equal monthly installments (1/48 of the total) over the following three years, subject to his continuous service.
Invivyd, Inc. director Ajay Royan received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $1.04 per share and expire on May 18, 2036. They vest in full on the earlier of May 19, 2027 or the company’s 2027 annual stockholders meeting, subject to Royan’s continuous service. Following this grant, he holds 50,000 options directly.
Invivyd, Inc. director Kevin F. McLaughlin received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $1.04 per share and expire on May 18, 2036. They vest in full on the earlier of May 19, 2027 or the company’s 2027 Annual Meeting of Stockholders, conditioned on his continuous service through that vesting date.
Invivyd, Inc. director Terrance McGuire received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $1.04 per share and expire on May 18, 2036. All 50,000 options were reported as directly owned following this grant.
According to the award terms, the option vests in full on the earlier of May 19, 2027 or the date of Invivyd’s 2027 annual meeting of stockholders, as long as McGuire continues to serve the company through that vesting date. This is a compensation-related grant, not an open‑market purchase or sale.
Invivyd, Inc. reported that director Marc Elia received a grant of stock options covering 50,000 shares of common stock at an exercise price of $1.04 per share. The options vest in full on the earlier of May 19, 2027 or the company’s 2027 Annual Meeting of Stockholders, subject to his continuous service, and expire on May 18, 2036. Following this award, Elia holds 50,000 stock options, which he is deemed to hold for the benefit of M28 Capital Management LP and funds managed by that firm.
Invivyd, Inc. reported that director Paul Bolno received a grant of stock options covering 32,876 shares of common stock. The options have an exercise price of $1.04 per share and expire on May 18, 2036. The grant vests in full on the earlier of May 19, 2027 or the date of Invivyd's 2027 Annual Meeting of Stockholders, provided he continues in service through that vesting date. After this grant, Bolno holds options for 32,876 underlying shares directly.
Invivyd, Inc. director Tamsin Berry received a compensation-related stock option grant covering 50,000 shares of common stock. The option has an exercise price of $1.0400 per share and expires on May 18, 2036. It vests in full on the earlier of May 19, 2027 or the company’s 2027 Annual Meeting of Stockholders, subject to her continuous service through the vesting date. Following this grant, she holds stock options for 50,000 shares directly.
Invivyd, Inc. Chief Scientific Officer Robert D. Allen III reported RSU vesting and related stock sales. He acquired 99,000 shares of common stock at $0.0000 per share through the exercise/conversion of restricted stock units and then sold 37,581 shares in open-market transactions.
The sales, at weighted average prices of $1.5396 and $1.5778 per share, were made under a non-discretionary sell-to-cover arrangement to satisfy tax withholding obligations pursuant to a Rule 10b5-1 plan. After these transactions, he directly held 114,487 shares of Invivyd common stock.
Invivyd, Inc.’s Chief Human Resources Officer Julie Green reported RSU vesting and related share sales. On February 15, she acquired 99,000 shares of common stock at $0.00 per share through the conversion of restricted stock units, increasing her direct common stock holdings.
On February 17 and 18, Green sold a total of 40,627 common shares in open-market transactions at weighted average prices of $1.5396 and $1.5778 per share. Footnotes explain these were non-discretionary “sell-to-cover” trades under a Rule 10b5-1 plan to satisfy tax withholding on the RSU vesting. After these transactions, she directly held 107,717 common shares.
Invivyd, Inc. Chief Financial Officer William E. Duke reported a mix of RSU vesting and related share sales. On February 15, 2026, he acquired 99,000 shares of common stock at no cost through the exercise of restricted stock units, leaving him with 148,344 shares.
On February 17 and 18, 2026, he sold 19,663 shares at a weighted average price of $1.5396 and 20,964 shares at a weighted average price of $1.5778 in open-market transactions. The company notes these were non-discretionary “sell-to-cover” sales to satisfy tax withholding obligations under a Rule 10b5-1 plan, and 107,717 shares of common stock remained held directly afterward.
Invivyd, Inc.’s Chief Commercial Officer Timothy Edward Lee reported a mix of stock sales and awards tied to restricted stock unit (RSU) vesting. On February 15, 2026, RSUs covering 99,000 shares were exercised at $0.00 per share and converted into common stock, with an RSU award scheduled to vest over eighteen months, one-third every six months from February 15, 2025.
On February 17 and 18, 2026, he sold a total of 40,627 common shares in open-market transactions at weighted average prices of about $1.54 and $1.58 per share. According to the disclosure, these sales were non-discretionary “sell-to-cover” transactions made solely to satisfy tax withholding obligations under a pre-established Rule 10b5-1 trading plan adopted on February 20, 2025. After these transactions, he reported owning 117,717 shares of common stock directly, including 10,000 shares acquired through the company’s Employee Stock Purchase Program, and 102,000 RSUs outstanding.
Invivyd, Inc. Chief Legal Officer and Secretary Jill Andersen reported a mix of stock activity involving restricted stock units (RSUs) and common shares. On February 15, RSUs covering 165,000 shares converted into common stock at a stated price of $0.0000 per share, reflecting an RSU vesting event. The RSU award vests over an eighteen-month period, with one-third vesting every six months following the February 15, 2025 grant date, conditioned on continued service.
To cover tax withholding from this vesting, Andersen executed non-discretionary "sell-to-cover" transactions under a Rule 10b5-1 plan adopted on February 20, 2025, selling 32,771 shares on February 17 at a weighted average price of $1.5396 and 34,939 shares on February 18 at a weighted average price of $1.5778. After these transactions, she directly held 181,736 shares of common stock, with an additional 500 shares held indirectly by her spouse.
Invivyd, Inc.’s Chief Financial Officer William E. Duke received a new stock option grant. On January 29, 2026, he was awarded options to purchase 625,000 shares of Invivyd common stock at an exercise price of $1.85 per share.
The options vest over three years, with 1/36th of the total vesting in substantially equal monthly installments starting one month after the grant date, contingent on his continuous service with the company.
Invivyd, Inc. reported that Chief Human Resources Officer Julie Green received a grant of stock options on January 29, 2026. The award covers 675,000 options to buy common stock at an exercise price of $1.85 per share, with no cash paid for the grant itself.
The options vest over three years, with 1/36th of the grant vesting in substantially equal monthly installments starting one month after the grant date, contingent on her continued service. Following this award, she holds 675,000 stock options directly.
Invivyd, Inc. reported a new equity award to its Chief Commercial Officer, Timothy Edward Lee. On January 29, 2026, he received a stock option to purchase 675,000 shares of common stock at an exercise price of $1.85 per share.
The option vests over three years, with 1/36th of the shares vesting in substantially equal monthly installments starting one month after the grant date, subject to his continuous service at each vesting date. Following this grant, he beneficially owns 675,000 derivative securities directly.
Invivyd, Inc. reported that its Chief Legal Officer and Secretary, Jill Andersen, received a new stock option award. On January 29, 2026, she was granted an option to buy 820,000 shares of Invivyd common stock at an exercise price of $1.85 per share.
The option vests over three years, with 1/36th of the shares vesting in substantially equal monthly installments starting one month after the grant date, conditioned on her continued service. After this grant, she beneficially owns 820,000 stock options directly.
Invivyd, Inc. granted a large stock option award to its Chief Scientific Officer. On January 29, 2026, Allen Robert D. III received a stock option covering 625,000 shares of Invivyd common stock at an exercise price of $1.85 per share.
The option vests over three years, with 1/36th of the shares vesting in substantially equal monthly installments starting one month after the grant date, conditioned on his continued service on each vesting date. Following this grant, he beneficially owns 625,000 derivative securities directly.
Invivyd, Inc. director reports purchase of common stock
A director of Invivyd, Inc. (IVVD) reported buying 50,000 shares of common stock on 11/19/2025. The Form 4 shows a transaction code "P" for a purchase at a price of $2.50 per share. After this transaction, the reporting person beneficially owns 50,000 shares, held directly. An accompanying note explains that these shares were acquired in an underwritten public offering of Invivyd common stock.
Paul Bolno, a director of Invivyd, Inc. (IVVD), was granted a stock option on 09/22/2025 to buy 100,000 shares of common stock at an exercise price of $1.22 per share. The option expires on 09/21/2035. The grant vests over three years: one-third vests on the first anniversary of the grant and the remainder vests in equal monthly installments (1/36th) thereafter, subject to continuous service through each vesting date. Following the grant, the reporting person beneficially owns 100,000 option shares, held directly. The Form 4 was filed with a signature dated 09/24/2025 by an attorney-in-fact.